An assessment of the protective effect of gonadotropin-releasing hormone agonist and antagonist on bleomycin-induced ovarian toxicity in rats

Abstract

The aim of this study is to evaluate the effect of GnRH agonist or GnRH antagonist therapy on bleomycin-administered rats by examining ovarian follicle counts and AMH levels. A total of 30 female Wistar albino rats aged 4–6 months were randomly divided into 4 groups. First, an intramuscular injection of bleomycin (30 mg/m²) was administered to all except the control group on the 1st, 8th and 15th days. The control group (Group I) was administered 0.1 mL intramuscular saline on those days. The bleomycin group (Group II) was followed up without any further treatment. The bleomycin + GnRH agonist group (Group III) was administered subcutaneous GnRH agonist triptorelin (1 mg/kg) at the same time as the bleomycin injections. The bleomycin + GnRH antagonist group (Group IV) was administered 1 mg/kg cetrorelix acetate subcutaneously, concurrently with the bleomycin. Although AMH levels were lower in the bleomycin group than in all the other groups, there was no statistically significant difference between the groups in terms of AMH levels (p > .05). In the bleomycin + cetrorelix acetate and bleomycin + triptorelin groups, significantly higher primordial, secondary and tertiary follicle counts were determined compared to the bleomycin group (p < .001). In conclusion the harmful effects of bleomycin on ovarian reserve can be reduced by the simultaneous administration of GnRH agonist or GnRH antagonist.

摘要

本研究的目的是通过检测卵巢的卵泡计数和AMH水平来评估GnRH激动剂和GnRH拮抗剂对博来霉素给药大鼠的影响。将30只4-6月龄的雌性Wistar白化病大鼠随机分为4组。首先, 除对照组外所有大鼠于第1、8和15天肌内注射博来霉素（30 mg / m2）。对照组（组I）在上述时间肌内注射盐水0.1mL。博来霉素组（组II）后续不进行任何治疗。博来霉素＋GnRH激动剂组（组III）在注射博来霉素的同时给予GnRH激动剂曲普瑞林皮下注射（1mg/kg）。博来霉素＋GnRH拮抗剂组（组IV）在注射博来霉素的同时给予GnRH拮抗剂醋酸西取瑞克皮下注射（1mg/kg）。尽管博来霉素组其AMH水平低于其他组, 但各组之间AMH水平无统计学差异（p> .05）。博来霉素＋醋酸西曲瑞克和博来霉素＋曲普瑞林组中原始、次级和三级卵泡计数显著多于博来霉素组（p <.001）。结论：同时应用GnRH激动剂或GnRH拮抗剂可以减少博来霉素对卵巢储备的损伤。

Keywords:

• Bleomycin
• ovarian reserve
• GnRH agonist
• GnRH antagonist
• AMH

Disclosure statement

No potential conflict of interest was reported by the author(s).